INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
Public company

Tevogen Inc.

TVGNCIK 0001860871

EDGAR filingsOpen in network
Price$5.56
1 year-80.0%
Disclosed transactions1
Buys / sells0 / 0
Max Insider Score21
Connections with evidence3

TVGN · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
21
SH
Saadi Ryan H.Director, Chief Executive Officer, 10% Owner
TVGNTevogen Inc.
Grant or award
A—
50.00M sh
Nov 2, 2026Nov 4, 2026

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2836 · Biological Products, (No Diagnostic Substances) · Nov 4, 2026
  • ← Insider ofevidence
    Saadi Ryan H.Director, Chief Executive Officer, 10% Owner · Nov 4, 2026
  • ← Holds over 5% ofevidence
    Saadi Ryan H.91.1% of class · Schedule 13D · Nov 3, 2026
traded Nov 2, 2026
+2d
SEC FORM 4

Evidence

Planned sales and 5% stakes

Form 144, 13D and 13G
  • SHSaadi Ryan H.May seek to influence the company · crossed on Nov 2, 2026 · 61.71M shares91.1% of class13D amendment · filed Nov 4, 2026